ANTARES PHARMA WKN: 903128 ISIN: US0366421065 Kürzel: ATRS Forum: Aktien Thema: Hauptdiskussion
5,25 EUR
±0,00 %±0,00
24. May, 10:31:31 Uhr,
Berlin
Kommentare 166
Summer.76,
29.03.2022 14:36 Uhr
0
Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy
https://www.globenewswire.com/news-release/2022/03/29/2411744/35385/en/Antares-Pharma-Announces-FDA-Approval-Of-TLANDO-an-Oral-Treatment-for-Testosterone-Replacement-Therapy.html
Commercial launch expected in 2Q 2022
Summer.76,
03.03.2022 13:33 Uhr
0
Antares Pharma Non-GAAP EPS of $0.02 beats by $0.01, revenue of $48.73M beats by $1.54M
https://seekingalpha.com/news/3808993-antares-pharma-non-gaap-eps-of-0_02-beats-0_01-revenue-of-48_73m-beats-1_54m
Antares Pharma press release (NASDAQ:ATRS): Q4 Non-GAAP EPS of $0.02 beats by $0.01.
Revenue of $48.73M (+10.5% Y/Y) beats by $1.54M.
The Company today provided its full-year 2022 revenue guidance range of $200 to $220 million, which does not include any unapproved products and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic. Excluding 2021 OTREXUP® proprietary revenue, the guidance range represents a 18% to 30% year-over-year growth rate vs. $211.38M consensus.
Summer.76,
03.03.2022 13:24 Uhr
0
Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results
https://www.globenewswire.com/news-release/2022/03/03/2396099/35385/en/Antares-Pharma-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-and-Operating-Results.html
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million
Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share
Full-Year 2021 Adjusted EBITDA of $39.2 Million
2022 Revenue Guidance Range of $200 to $220 Million
Summer.76,
03.02.2022 15:35 Uhr
0
Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®
https://www.globenewswire.com/news-release/2022/02/03/2378482/35385/en/Antares-Pharma-Announces-FDA-Acceptance-of-NDA-Resubmission-for-TLANDO.html
PDUFA target action date set for March 28, 2022
Summer.76,
16.12.2021 8:12 Uhr
0
Antares Pharma Announces Divestiture of Otrexup®
https://www.globenewswire.com/news-release/2021/12/15/2353151/0/en/Antares-Pharma-Announces-Divestiture-of-Otrexup.html
...today announced the divestiture of OTREXUP® (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of Assertio Holdings, Inc., a commercial pharmaceutical company, for a total cash consideration of $44.0 million inclusive of OTREXUP® WIP and finished inventory. Under the terms of the asset purchase agreement, Antares will receive an initial payment of $18.0 million at closing plus two additional time-based payments totalling $26.0 million in 2022. ...
Summer.76,
30.11.2021 17:14 Uhr
0
Antares Pharma Granted U.S. Patent #11,185,642 'Injection device with cammed ram assembly'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6129&f=G&l=50&d=PTXT&p=123&S1=20211130&OS=20211130&RS=20211130
Summer.76,
08.11.2021 21:40 Uhr
0
https://finance.yahoo.com/news/lpcn-antares-agreement-nash-fast-131800309.html
Summer.76,
04.11.2021 15:51 Uhr
0
Antares Pharma Reports Third Quarter 2021 Financial and Operating Results
https://www.globenewswire.com/news-release/2021/11/04/2327256/35385/en/Antares-Pharma-Reports-Third-Quarter-2021-Financial-and-Operating-Results.html
Increased Revenue 20% Year-Over-Year to $48.2 Million
Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share
Summer.76,
03.11.2021 7:47 Uhr
0
Antares Pharma Enters Into Credit Agreement For Credit Facilities Of Up To $40 Million
https://last10k.com/sec-filings/atrs/0001016169-21-000034.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=atrs
Summer.76,
18.10.2021 17:39 Uhr
0
Antares Pharma Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S.
https://finance.yahoo.com/news/antares-pharma-enters-exclusive-license-110000356.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACmcGvCVMgXvJisyH7dENdV43bZ9G9OSnQ1kKolpY7XMcXw_pP1W507Dyb9F7Q1crjWuV7kbV-hAr1VMpRk1YIqYv1GmCx7S1jNC0HOwRHg58A3uV1qMVHt8eWMl_RM62gozApJBgLrzIrSagRGR1HZXr3s1v92xV9vwlDNA9Eo4
Summer.76,
30.09.2021 17:33 Uhr
0
Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
https://www.globenewswire.com/news-release/2021/09/30/2306251/35385/en/Antares-Pharma-Initiates-Phase-I-Study-For-ATRS-1902-For-Adrenal-Crisis-Rescue.html
Pharmacokinetic data results expected in 1Q 2022
Summer.76,
05.08.2021 14:49 Uhr
0
Antares Pharma Reports Second Quarter 2021 Financial and Operating Results
https://www.globenewswire.com/news-release/2021/08/05/2275394/35385/en/Antares-Pharma-Reports-Second-Quarter-2021-Financial-and-Operating-Results.html
Increased Revenue 39% Year-Over-Year to $45.0 Million
Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share
...
Summer.76,
22.07.2021 17:03 Uhr
0
Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue
https://www.globenewswire.com/news-release/2021/07/22/2267319/35385/en/Antares-Pharma-Announces-FDA-Acceptance-of-IND-Application-for-ATRS-1902-for-Adrenal-Crisis-Rescue.html
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | ASPENBIO Hauptdiskussion | +2,73 % | |
2 | GAMESTOP Hauptdiskussion | +25,53 % | |
3 | PAYPAL Hauptdiskussion | -2,22 % | |
4 | BTC/USD Hauptdiskussion | +6,31 % | |
5 | Aktien und Saunaclub alla Luci | ||
6 | MICROSTRATEGY Hauptdiskussion | +9,33 % | |
7 | BED BATH & BEYOND Hauptdiskussion | -28,27 % | |
8 | Das neue Dax Prognose Forum | +0,47 % | |
9 | NVIDIA Hauptdiskussion | +2,36 % | |
10 | Canopy Hauptforum | -1,14 % | Alle Diskussionen |
Anzeige
Aktien
|
Thema | ||
---|---|---|---|
1 | ASPENBIO Hauptdiskussion | +2,73 % | |
2 | GAMESTOP Hauptdiskussion | +25,53 % | |
3 | PAYPAL Hauptdiskussion | -2,22 % | |
4 | MICROSTRATEGY Hauptdiskussion | +9,33 % | |
5 | BED BATH & BEYOND Hauptdiskussion | -28,27 % | |
6 | NVIDIA Hauptdiskussion | +2,36 % | |
7 | Canopy Hauptforum | -1,14 % | |
8 | Lilium Aktie | +2,15 % | |
9 | TUPPERWARE Hauptdiskussion | +17,31 % | |
10 | AFC ENERGY Hauptdiskussion | -0,58 % | Alle Diskussionen |